Delcath Systems earnings date
Delcath Systems (DV3R) Q3 2026 Earnings Report
DE:DV3R Q3 2026 EPS Results
- Actual EPS
- EUR 0.15
- Consensus EPS
- -EUR 0.08
- Beat/Miss
- Beat by +EUR 0.24
- One Year Ago EPS
- EUR 0.02
DE:DV3R Q3 2026 Revenue Results
- Actual Revenue
- EUR 31.84M
- Expected Revenue
- EUR 23.58M
- Beat/Miss
- Beat by +EUR 8.26M
- YoY Revenue Growth
- +70.70%
Earnings Announcement Details
- Quarter
- Q3 2026
- Date
- 11/09/2026
- Time
- Before Open
- Conference Call
- Monday, November 9, 2026
Delcath Systems's next earnings date is estimated for March 30, 2027, based on past reporting schedules.
Q3 2026 Earnings Call Audio
Q3 2026 Earnings Slide Deck
No slide deck is available for this earnings event.
Q3 2026 Earnings Call Summary
The call was strongly positive, led by record revenue, rapid HEPZATO adoption, expanding treatment-center capacity, improved profitability, positive operating cash flow, a strong cash position, and raised full-year guidance. The principal challenges were slower-than-expected breast cancer trial enrollment and expected holiday-related fourth-quarter seasonality, but these were outweighed by the commercial and financial progress.
For 2026, Delcath raised full-year total revenue guidance to a range of $115 million to $117 million, expects at least a 41% HEPZATO KIT volume growth over 2025, and guides to $25.8 million to $27.8 million total revenue in the fourth quarter of 2026, a year-on-year growth of approximately 25% to 34%, full-year gross margin of 87% to 89%, and positive adjusted EBITDA; it expects at least one more activation before year-end, which would bring the network to at least 36 centers by year-end, while fourth-quarter new patient starts are generally expected to be fewer than in other quarters, with last year’s Q4 new patient starts at 0.3 to 0.35, the Phase II colorectal trial supports an interim analysis in the middle of next year, the cholangiocarcinoma program has a planned IND submission in early 2027, and completion of the ongoing preclinical development of an oxaliplatin-based PHP program is expected by mid-2027, pending FDA agreement; R&D spending is probably more of the norm to increase quarter-over-quarter as we go into 2027, SG&A is likely a little bit more flat of a growth going into the fourth quarter and then next year but will flex a bit with the increase in sales quarter-over-quarter, and the 340B changes are expected to be net neutral to a net positive in terms of ASP without any impact on volume one way or the other.
- Record Revenue and HEPZATO GrowthThird-quarter 2026 total revenue reached a record $35.1 million, up 71% from $20.6 million in the third quarter of 2025. HEPZATO KIT revenue was $32.7 million versus $19.3 million, with HEPZATO volume up 19% sequentially and 72% year-over-year. CHEMOSAT revenue was $2.4 million compared with $1.3 million in the prior-year quarter.
- Improved Profitability and Operating Cash FlowGross margin increased to 89% from 87% in the prior-year quarter. Net income rose to $7 million from $0.8 million, while adjusted EBITDA increased to $11.5 million from $5.3 million. Cash generated from operations was $8.2 million versus $4.8 million in the prior-year quarter, and management stated that the company delivered positive operating cash flow.
- Strong Cash Position With No DebtDelcath ended the quarter with $104.3 million in cash and investments and no debt.
- Treatment-Center Network ExpansionThe company reached 33 active U.S. treatment centers after adding the University of Nebraska and AdventHealth. Two additional centers had patients scheduled, and management expected at least one more activation before year-end, which would bring the total to at least 36 centers.
- AdventHealth Provides a Broad Referral PlatformManagement highlighted AdventHealth as one of the nation's largest integrated health systems, with more than 50 hospitals, over 2,000 care sites, and roughly 4 million unique patients served annually. Its integrated network includes primary care centers and general oncologists that can refer patients with metastatic uveal melanoma to HEPZATO treatment centers.
- Broad-Based New Patient Starts and Increased Center CapacityNew patient starts were approximately 0.6 per site per month in the third quarter. Management said the activity was broad-based across treatment centers, with larger centers such as MD Anderson and Mass General increasing treatment-team capacity and enrolling more new patients.
- Growing Adoption of Combination and Sequencing TherapyManagement said combination treatment with systemic therapy is increasingly becoming the norm, with physicians viewing systemic therapy and PHP as complementary rather than mutually exclusive. CHOPIN has provided an important foundation for this strategy, and combination therapy may result in patients remaining on therapy longer and receiving more doses.
- Drivers of Quarterly OutperformanceManagement attributed the strong quarter to increasing use of combination or sequencing therapy, physicians seeing results and patients increasingly asking for HEPZATO, reduced headwinds from clinical trials compared with the prior year, and the company's work to establish backup perfusionist, anesthesiologist, and interventional-radiology teams that increased center scheduling capacity.
- Commercial Treatment MilestonesThe 1,000th commercial HEPZATO treatment in the United States took place during the third quarter. University Hospital Southampton also delivered its 500th CHEMOSAT procedure, led by Dr. Sachin Modi.
- Colorectal Cancer Trial ProgressThe Phase II colorectal cancer trial continued enrolling at a pace that supports an interim analysis around the middle of next year, with management indicating that an update could come in the second or third quarter.
- Expansion of the Clinical PipelineDelcath plans to submit an IND for cholangiocarcinoma in early 2027. Subject to FDA agreement, the company expects to complete ongoing preclinical development of an oxaliplatin-based PHP program by mid-2027 to support a subsequent IND. Management said the cholangiocarcinoma program has broad medical-community support and that physicians are familiar with oxaliplatin as a backbone agent in colorectal and other gastrointestinal cancers.
- Raised 2026 Revenue GuidanceThe company raised full-year 2026 total revenue guidance to $115 million to $117 million. It expects at least 41% HEPZATO KIT volume growth over 2025, fourth-quarter revenue of $25.8 million to $27.8 million representing approximately 25% to 34% year-over-year growth, full-year gross margin of 87% to 89%, and positive adjusted EBITDA.
- Continued Investment in Clinical and Commercial ExpansionResearch and development expense increased to $11 million from $8 million, primarily reflecting additional clinical headcount and increased clinical-trial activity. Selling, general, and administrative expense increased to $13.1 million from $10.3 million, reflecting continued investment in commercial expansion. Management said R&D spending is likely to increase quarter over quarter into 2027, while SG&A is expected to be relatively flatter after staffing the commercial team across nine regions, with some flexibility based on sales.
- Expected 340B ImpactRegarding the recently posted 340B final rules, management said it expects the changes to be net neutral to net positive for average selling price, without an impact on volume in either direction.
DE:DV3R Earnings History
| Report Date | Fiscal Quarter | Forecast / EPS | Last Year's EPS | EPS YoY Change | Press Release |
|---|---|---|---|---|---|
| Mar 30, 2027 | 2026 (Q4) | -0.05- | -0.05 | ― | ― |
| Nov 09, 2026 | 2026 (Q3) | -0.080.15 | 0.02 | 750.00% (+0.14) | |
| Aug 06, 2026 | 2026 (Q2) | -0.080.06 | 0.06 | 0.00% (+0.00) | |
| May 07, 2026 | 2026 (Q1) | -0.09-0.03 | 0.03 | -200.00% (-0.05) | |
| Feb 26, 2026 | 2025 (Q4) | -0.06-0.05 | -0.1 | 54.55% (+0.05) | |
| Nov 04, 2025 | 2025 (Q3) | -0.000.02 | 0.05 | -66.67% (-0.04) | |
| Aug 06, 2025 | 2025 (Q2) | 0.020.06 | -0.44 | 114.58% (+0.50) | |
| May 08, 2025 | 2025 (Q1) | 0.020.03 | -0.41 | 106.67% (+0.44) | |
| Mar 06, 2025 | 2024 (Q4) | -0.00-0.10 | -0.44 | 77.08% (+0.34) | |
| Nov 08, 2024 | 2024 (Q3) | -0.180.05 | -1.03 | 105.26% (+1.09) |
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

